The new international guidelines for diagnosing Alzheimer’s

The new international guidelines for diagnosing Alzheimer’s

An important breakthrough has emerged in the field of diagnostics Alzheimer disease thanks to new international guidelines published by a committee of world-renowned clinicians and researchers. The International Alzheimer’s Association and the American National Institute on Aging have been the promoters of this roadmap in the fight against neurodegenerative disease.

Presented at the International Alzheimer’s Congress in Amsterdam, these guidelines state that the diagnosis of the disease can be made in the clinic through the use of blood biomarkers. This approach follows the same principle applied in major diseases such as diabetes and cardiovascular disease.

Professor Charlotte Teunissen, Professor of Neurochemistry at UMC Amsterdam and one of the guideline authors, commented:

“We now have a new generation of biomarkers that allows us to detect Alzheimer’s disease more and more effectively. We have already gained a lot of experience in our Alzheimer’s center, but in the long term, this test can also be applied successfully after a referral from the GP.”

Previously, diagnosis was based on identification of brain pathology and the cognitive impairment characteristic of the disease. However, in these new guidelines, it has been established that the diagnosis will be made using biomarkers.

The authors also note that this new approach is gaining momentum due to the approval of targeted therapies, such as the drug lecanemab, in the United States. (DOMENECH CASTELLO)

The document highlights the development and clinical validation of several biomarkers in recent years, all of them with excellent diagnostic performance, and anticipates the arrival of more advances in this field.

The authors also note that this new approach is gaining momentum due to the approval of targeted therapies, such as the drug lecanemab, in the United States. This opens up new perspectives in the fight against Alzheimer’s and gives hope to patients and their families.

An early diagnosis gives patients more control over the next phase of their lives. “The desire to know whether or not you have Alzheimer’s disease makes the use of blood biomarkers so relevant, in addition to being the gateway to treatment”, the experts emphasize.

Besides, the researchers stress that blood testing as a diagnostic method is relatively inexpensive and can be performed in a variety of settings. This marks a significant difference compared to the past, where only specialized clinics could perform proper testing, which meant higher costs and a greater burden on patients.

It should be noted that currently Alzheimer’s diagnosis is made by invasive removal of cerebrospinal fluid via lumbar puncture or expensive PET scans. However, it is expected that these methods will become less necessary in the near future thanks to advances in the use of blood biomarkers.

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!